# Wave Life Sciences, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Wave Life Sciences, Inc.).

## Overview

Wave Life Sciences, Inc. is a clinical-stage biotechnology company developing RNA medicines for genetic and metabolic diseases. Its platform includes stereopure oligonucleotide design, RNA editing, RNA interference, and other nucleic-acid approaches, with research and development activities conducted through operations in the United States, Japan, Ireland, and the United Kingdom.

## Products & services

• WVE-007 INHBE GalNAc-siRNA for obesity
• WVE-006 GalNAc-RNA editing for AATD
• WVE-008 RNA editing for PNPLA3 liver disease
• WVE-N531 exon-skipping therapy for Duchenne muscular dystrophy
• PRISM oligonucleotide discovery and development platform

- **RNA editing medicines** (30%) — GalNAc-delivered candidates designed to correct or alter disease-associated RNA in liver disorders.
- **RNA interference medicines** (25%) — siRNA programs designed to silence disease-related genes, including the INHBE obesity program.
- **Antisense and exon-skipping medicines** (20%) — Oligonucleotide therapies intended to modify RNA processing in genetic diseases such as DMD.
- **Discovery platform and collaborations** (25%) — PRISM-enabled research programs and partnered oligonucleotide discovery activities.

- WVE-007 INHBE GalNAc-siRNA for obesity
- WVE-006 GalNAc-RNA editing for AATD
- WVE-008 RNA editing for PNPLA3 liver disease
- WVE-N531 exon-skipping therapy for Duchenne muscular dystrophy
- PRISM oligonucleotide discovery and development platform

## Customers

Wave has not generated product revenue and currently derives revenue from collaboration agreements rather than sales to patients or healthcare providers. Its commercial counterparties are biopharmaceutical companies seeking RNA drug discovery, development, licensing, and commercialization capabilities, including GSK and previously Takeda. Future customers could include healthcare systems, physicians, payors, and patients if Wave's clinical candidates receive regulatory approval.

- **Biopharmaceutical collaborators** (primary) — Large drug companies partner with Wave to access RNA biology, PRISM, and development expertise.
- **Licensing and commercialization partners** (secondary) — Potential partners may license late-stage or approved candidates for global regulatory and commercial execution.
- **Healthcare providers and payors** (emerging) — Future providers and insurers could purchase or reimburse approved medicines for eligible patients.
- **Patients with genetic and metabolic diseases** (emerging) — Patients are the intended end users of treatments for obesity, AATD, liver disease, DMD, and other conditions.

- GSK funds and collaborates on oligonucleotide discovery programs
- Biopharma partners access PRISM and RNA development capabilities
- Future licensees may commercialize approved Wave medicines
- Physicians and healthcare systems may use approved therapies
- Patients with genetic or metabolic diseases are the end beneficiaries

## Geography

Wave's principal U.S. operations are based in Cambridge, Massachusetts, while subsidiaries and registered offices are located in Japan, Ireland, and the United Kingdom. Research, clinical development, manufacturing coordination, regulatory activity, and collaboration management therefore span North America, Europe, and Asia. The company does not disclose country-level product revenue, and reported revenue has come from collaboration agreements rather than geographic product sales.

- Cambridge, Massachusetts is the principal U.S. operating location
- Japan supports group operations through Wave Japan
- Ireland and the UK provide European corporate operations
- Clinical and regulatory activities span multiple global jurisdictions
- No country-level product revenue is disclosed

## Strategy

Wave's strategy is to advance a focused pipeline of RNA medicines while using its PRISM platform and delivery technologies to expand the addressable range of genetic and metabolic diseases. Near-term development centers on WVE-007 for obesity and RNA-editing candidates WVE-006 and WVE-008, while partnerships such as the GSK collaboration provide external validation, potential funding, and commercialization access. The model remains dependent on clinical execution, regulatory progress, and the ability to convert research programs into licensing or product opportunities.

- **Advance WVE-007 in obesity** (short-term) — Obesity is a large market where durable dosing and muscle preservation could differentiate the program.
- **Develop RNA-editing programs** (short-term) — RNA editing may enable durable treatment approaches for genetically defined liver diseases.
- **Expand the partnered discovery pipeline** (medium-term) — Collaborations can provide capital, genetic insights, and commercial capabilities beyond Wave's internal resources.
- **Build a diversified RNA medicines portfolio** (long-term) — Multiple modalities and disease areas reduce dependence on any single clinical candidate.

- Advance WVE-007 through obesity clinical development
- Progress WVE-006 toward regulatory and clinical milestones
- Prepare WVE-008 for clinical development in PNPLA3 liver disease
- Use PRISM to generate additional partnered programs
- Retain optionality through licensing and collaborations

## Risks

Wave's value depends on advancing clinical-stage candidates through trials and regulatory review, with no product revenue to offset research and development spending. Clinical failures, safety findings, manufacturing or enrollment problems, and competition from other RNA and obesity therapies could reduce the value of its pipeline. Collaboration concentration, future capital needs, intellectual-property disputes, and cyber incidents affecting Wave or its external providers add financial and operational exposure.

- **Clinical and regulatory failure** [critical] — Candidate medicines must demonstrate safety and efficacy in trials and satisfy regulators before generating product revenue.
- **Funding and continuing losses** [critical] — Wave has recurring operating losses and no product revenue, so development depends on capital markets and collaboration proceeds.
- **Collaboration concentration** [high] — Collaboration revenue and future milestone potential depend materially on partners' continued investment and performance.
- **Clinical supply and outsourcing dependence** [high] — CROs and CMOs perform important research, trial, and manufacturing activities that may be delayed or disrupted.
- **Cybersecurity and data privacy** [high] — Breaches could compromise patient health information, intellectual property, research data, and business systems.
- **Competitive technology and market adoption** [high] — Competing RNA, gene therapy, obesity, and conventional medicines may limit differentiation or reduce commercial uptake.

- Clinical candidates may fail to demonstrate safety or efficacy
- Regulatory delays could postpone approvals and commercial opportunities
- No product revenue leaves the model dependent on capital and partners
- GSK concentration increases exposure to collaboration decisions
- CRO, CMO, and clinical supply failures could disrupt trials
- Cyberattacks could expose patient, research, and business data

## Accounting

Wave prepares its financial statements under U.S. GAAP, with collaboration revenue recognized under contract-performance accounting rather than from product sales. Significant judgments include identifying performance obligations, estimating transaction price and milestone consideration, allocating contract consideration, and determining the timing of revenue recognition. Estimates of CRO and CMO costs, refundable tax credits, leases, and research program expenses can also affect period-to-period comparability.

- **Collaboration revenue recognition** — Changes in estimates can shift revenue between reporting periods and materially affect reported results.
- **Milestone and variable consideration** — Milestone recognition can create significant revenue volatility when contractual conditions are met.
- **CRO and CMO accruals** — Revisions to estimated activity or costs can change research and development expense.
- **Refundable tax credits** — Timing of recognition affects other income and reported net loss.
- **Operating leases** — Lease classification and expense recognition affect liabilities, operating expenses, and cash-flow presentation.

- Collaboration revenue timing depends on performance obligations
- Milestone consideration may require estimates and constraint judgments
- GSK and Takeda contracts have affected revenue comparability
- CRO and CMO cost estimates affect research expense timing
- Refundable tax credits affect other income when realizability is assured
- Lease commitments affect liabilities and future operating expenses

---

*Last updated: 2026-09-24T11:26:48.866251+00:00*